PDCD1 and diffuse large B-cell lymphoma: Treatment of DLBCL using PD-1 inhibitors is also of increasing general interest (33, 34); however, anti-PD-1 treatment has poor efficacy, with a less than 40% objective remission rate for the treatment of patients with relapsed/refractory DLBCL (35).